Invasive Pulmonary Fungal Infections in Cystic Fibrosis

被引：0
作者：
Carsten Schwarz
Claudia Brandt
Paul Whitaker
Sivagurunathan Sutharsan
Heino Skopnik
Silvia Gartner
Christina Smazny
Jobst F. Röhmel
机构：
[1] Charité – Universitätsmedizin Berlin,
[2] Corporate Member of Freie Universität Berlin,undefined
[3] Humboldt-Universität zu Berlin,undefined
[4] and Berlin Institute of Health,undefined
[5] Leeds Teaching Hospitals NHS Trust,undefined
[6] Universitatsklinikum Essen,undefined
[7] Klinikum Worms,undefined
[8] Hospital Vall d’Hebron,undefined
[9] Klinikum der Johann Wolfgang Goethe-Universitat Frankfurt,undefined
来源：
Mycopathologia | 2018年 / 183卷
关键词：
Invasive pulmonary mycosis; Cystic fibrosis; Non-ABPA infections;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Invasive pulmonary mycosis is after allergic bronchopulmonary aspergillosis (ABPA) a frequent and severe complication of CF lung disease. Among CF caregivers, there is an insecurity when and how to treat infections of the lung parenchyma caused by different fungi in patients with CF. This case series provides a multicenter experience on diagnostic, manifestation, and treatment of non-ABPA cases of pulmonary. Non-ABPA cases of pulmonary mycoses in patients with CF have been collected from the CF Centers in Berlin, Essen, Worms, Frankfurt (Germany), Leeds (UK), and Barcelona (Spain). Non-ABPA was defined as total serum IgE level <500 kU/L. Scedosporium and Lomentospora species seem to be more virulent in patients with CF and have been successfully treated with triple antifungal drug regimens in several cases. Rare fungi including yeasts can have pathogenic potential in CF. In this series, antibiotic treatment failure was the main indicator for the initiation of antifungal treatment. For an early and effective treatment of pulmonary mycoses in CF, the identification of biomarkers and of risk factors beyond antibiotic treatment failure is crucial and urgently needed. Furthermore, treatment efficacy studies are necessary for the different causative agents of these infections.
引用
收藏
页码：33 / 43
页数：10
相关论文
共 73 条
[1]  
Kerem E(1992)Prediction of mortality in patients with cystic fibrosis N Engl J Med 326 1187-1191
[2]  
Reisman J(2010)Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations Am J Respir Crit Care Med 182 298-306
[3]  
Corey M(2003)Pseudomonal infection in cystic fibrosis: the battle continues Expert Rev Anti Infect Ther 1 609-618
[4]  
Canny GJ(2015)Clinical outcomes after initial Pediatr Pulmonol 50 42-48
[5]  
Levison H(2007) acquisition in cystic fibrosis J Pediatr 151 134-139
[6]  
Flume PA(2016)Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis Med Mycol 54 781-786
[7]  
Mogayzel PJ(2013)Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center Curr Opin Pulm Med 19 670-675
[8]  
Robinson KA(2000)Fungal infections and treatment in cystic fibrosis Eur Respir J 16 464-471
[9]  
Elkin S(2015)Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic registry of cystic fibrosis Clin Exp Allergy 45 1765-1778
[10]  
Geddes D(2009)Prevalence of Chest 135 805-826
12345678